Skip to main content

UPS Healthcare Enhances Dry Ice Production Capabilities, Launches Mobile Freezer Storage Units

Written by Customer Service on . Posted in Public Companies.

ATLANTA, Nov. 24, 2020 (GLOBE NEWSWIRE) —Enhanced capability allows UPS Healthcare to produce 1,200 lbs. of dry ice per hour in the U.S. and Canada.UPS Healthcare is collaborating with Stirling Ultracold to supply portable freezers for storage of vaccines at a range of -20°C to -80°C.Services are in response to complex, urgent demands for approved COVID-19 vaccine storage and distribution efforts when the time comes.UPS (NYSE:UPS) today announced service enhancements to aid in the massive distribution efforts for COVID-19 vaccines in the coming months. As part of these enhancements, UPS Healthcare now can produce up to 1,200 lbs. of dry ice per hour in its U.S. facilities to support the storage and transportation of cold chain products, such as frozen vaccines, in accordance with manufacturer storage requirements. The increased production also allows UPS to make dry ice available for U.S. and Canadian hospitals, clinics and other points of care requiring dry ice to store vaccines locally. Dry ice will be sourced at UPS Worldport® and can be available next day.A major spike in demand is causing logistics providers to plan for what some analysts fear may be a dry ice shortage, as pharmaceutical companies strategize getting hundreds of millions of their vaccine doses safely to communities around the U.S. and internationally.“Enhancing our dry ice production capabilities increases our supply chain agility and reliability immensely when it comes to handling complex vaccines for our customers,” says Wes Wheeler, president of UPS Healthcare. “Healthcare facilities in Louisville, Dallas and Ontario will ensure we have the capability to produce dry ice to sufficiently pack and replenish shipments as needed to keep products viable and effective.”In addition to dry ice production, UPS will also launch, in collaboration with Stirling Ultracold, a joint effort to provide portable ultra-low temperature (ULT) freezers. These portable freezers will be distributed and used in smaller point of care facilities requiring a more permanent solution for longer term freezer storage. UPS will be working with Stirling to offer the Stirling ULT25 and Undercounter Model SU105 to thermally protect critical vaccines requiring ultra-low temperatures ranging anywhere from -20°C to -80°C.“We are truly proud to partner with UPS in this critical effort. As the leading manufacturer of small and portable ULT devices, Stirling Ultracold freezers integrate well with UPS Healthcare logistics to provide complete cold-chain of custody for COVID-19 vaccines from the drug manufacturers to medical facilities,” says Dusty Tenney, CEO of Stirling. “This program will help ensure vaccines remain effective next year, and for years to come, as future vaccines and biologics are developed to keep the world healthy and safe.”About UPS HealthcareUPS Healthcare operates 128 facilities in 32 countries which are regulated under Good Manufacturing Practices (GMP). UPS Healthcare services include: inventory management, temperature-controlled packaging and shipping, storage and fulfillment of medical devices, labs and clinical trial logistics. UPS Healthcare’s global infrastructure, its newest UPS Premier® visibility service, its track and trace technology, and its global quality system are well-suited to meet today’s complex logistics demands for the pharmaceutical, medical device and laboratory diagnostic industries. Visit ups.com/healthcare.UPS Media Relations
404-828-7123
pr@ups.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.